Morgan Stanley and J.P. Morgan are bookrunners; Cowen is lead manager
By Devika Patel
Knoxville, Tenn., Feb. 3 – Editas Medicine, Inc. said it priced its $94.4 million initial public sale of stock with a $14.16 million greenshoe on Tuesday.
The company will sell 5.9 million common shares at $16.00 per share.
Morgan Stanley and J.P. Morgan are the bookrunners.
Proceeds will be used to fund the ongoing development of CTP-354 for spasticity associated with multiple sclerosis and spinal cord injury, for research and development efforts to advance the company’s pipeline of additional product candidates and for working capital and other general corporate purposes.
The genome editing company is based in Cambridge, Mass. The company plans to list its shares on the Nasdaq under the symbol “EDIT.”
| Issuer: | Editas Medicine, Inc.
|
| Issue: | Common stock
|
| Amount: | $94.4 million
|
| Greenshoe: | $14.16 million, or 885,000 shares
|
| Shares: | 5.9 million
|
| Price: | $16.00
|
| Warrants: | No
|
| Bookrunners: | Morgan Stanley and J.P. Morgan
|
| Lead manager: | Cowen and Co.
|
| Co-manager: | JMP Securities
|
| Pricing date: | Feb. 2
|
| Stock exchange: | Nasdaq: EDIT
|
|
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
